Literature DB >> 29522133

Varicella Outbreak Surveillance in Schools in Sentinel Jurisdictions, 2012-2015.

Adriana S Lopez1, Bethany LaClair2, Vicki Buttery3, Yufang Zhang4, Jennifer Rosen5, Elizabeth Taggert6, Sara Robinson7, Mychal Davis8, Catherine Waters9, Carrie A Thomas10, Carmen Rodriguez11, Ebony Thomas2, Jessica Tuttle2, Tamara Brantley5, Dana Perella6, Maria Del Rosario10, Mona Marin1.   

Abstract

BACKGROUND: In 2007, a routine second dose of varicella vaccine was recommended in the United States for children aged 4 to 6 years to better control varicella-zoster virus circulation and outbreaks. Sentinel varicella outbreak surveillance was established to assess feasibility of surveillance and describe outbreaks that are occurring.
METHODS: Through the Centers for Disease Control and Prevention Epidemiology Laboratory Capacity funding, health departments conducted active surveillance for varicella outbreaks in schools from 2012 to 2015. Outbreaks of varicella were defined as ≥5 cases in a school within at least 1 incubation period (21 days). School nurses, healthcare providers, or laboratories reported cases and outbreaks of varicella to health departments; demographic, vaccination, and clinical data were collected.
RESULTS: Georgia, Houston, Maine, Minnesota, New York City, and Philadelphia participated in all 3 years; Puerto Rico and West Virginia participated in 2012 to 2013; and Kansas and Arkansas participated in 2014 to 2015. Twenty-nine outbreaks including 262 cases were reported. The median size of the outbreaks was 7 cases (range, 5-31 cases), and the median duration was 31 days (range, 4-100 days). Of the case-patients associated with larger outbreaks (≥8 cases), 55.4% were unvaccinated, and 15.7% and 18.1% had received 1 or 2 doses of vaccine, respectively. In small outbreaks (5-7 cases), 33.3% of case-patients were unvaccinated, and 16.7% and 38.5% had received 1 or 2 doses of vaccine, respectively.
CONCLUSIONS: The majority of cases associated with outbreaks occurred in undervaccinated children (unvaccinated and 1-dose vaccine recipients). Outbreaks with a greater proportion of 2-dose vaccine recipients were smaller. Varicella outbreak surveillance is feasible, and continued monitoring of outbreaks remains important for describing the epidemiology of varicella during the 2-dose varicella vaccination program. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society 2018.

Entities:  

Keywords:  outbreak surveillance; varicella; varicella outbreaks

Mesh:

Substances:

Year:  2019        PMID: 29522133     DOI: 10.1093/jpids/piy010

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  5 in total

1.  Clinical characteristics and risk factors associated with breakthrough varicella during varicella outbreaks.

Authors:  Wei Qin; Xiao-Kang Xu; Yao Wang; Xiang-Mei Meng; Cheng-Wu Yang; Feng Xia; Hong Su
Journal:  Hum Vaccin Immunother       Date:  2020-03-02       Impact factor: 3.452

2.  Varicella outbreaks in schools and kindergartens in Shanghai, China from 2011 to 2020.

Authors:  Jing Wang; Zhenhui Xu; Qiang Gao
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

3.  Changes in epidemiological characteristics and sero-prevalence against the varicella zoster virus in school-age children after the introduction of a national immunization program in Japan.

Authors:  Yosuke Yasui; Toshikatsu Mitsui; Fujiyo Arima; Keiko Uchida; Mikako Inokuchi; Mitsuaki Tokumura; Tetsuo Nakayama
Journal:  Hum Vaccin Immunother       Date:  2021-03-02       Impact factor: 3.452

Review 4.  Varicella-zoster virus post-exposure management and prophylaxis: A review.

Authors:  Anne M Lachiewicz; Megan L Srinivas
Journal:  Prev Med Rep       Date:  2019-11-06

5.  Reconstructing the transmission dynamics of varicella in Japan: an elevation of age at infection.

Authors:  Ayako Suzuki; Hiroshi Nishiura
Journal:  PeerJ       Date:  2022-01-19       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.